Abstracts tagged "Diagnostic Tests"

Abstract Number: 1484 • 2018 ACR/ARHP Annual Meeting
Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort
Maresa Grundhuber¹, Daniela Sieghart², Günter Steiner², Maryam Poorafshar³ and Sascha Swiniarski¹, ¹Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, ²Division of Rheumatology, Department of Internal Medicine III, Medical University Vienna, Austria, Vienna, Austria, ³Thermo Fisher Scientific, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) leading to effective treatment is essential to improve prognosis and to prevent disease progression. Anti-cyclic citrullinated peptide (CCP)…
Abstract Number: 1485 • 2018 ACR/ARHP Annual Meeting
Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia
Malin C Erlandsson^1,2, Minna Turkkila³, Rille Pullerits^2,3,4 and Maria I Bokarewa^2,3, ¹Department of rheumatology and inflammation research, University of Gothenburg, Gothenburg, Sweden, ²Rheumatology Clinic, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Rheumatology, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ⁴Department of Clinical immunology and transfusion medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Background/Purpose: Early recognition of rheumatoid arthritis (RA) is believed to be the key to successful treatment of this disease. Symptoms of arthralgia often predate development…
Abstract Number: 1693 • 2018 ACR/ARHP Annual Meeting
Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
Melissa E. Munroe^1,2, Joel M. Guthridge¹, Rufei Lu^1,3, Joseph M. Kheir¹, Bolanle Adebayo¹, Susan R. Macwana¹, Hua Chen¹, Virginia C. Roberts¹, Mohan Purushothaman², Sanjiv Sharma², Teresa Aberle¹, Stan Kamp¹, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹ and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease marked by immune dysregulation. A comprehensive but cost-effective tool to track relevant mediators of altered…
Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Thierry Dervieux¹, Laura Martinez Prat², John Conklin¹, Claudia Ibarra¹, Michael Mahler², Michael E Weinblatt³ and Joel Kremer⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
Abstract Number: 1368 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Identifies Plasma microRNA Panel for Rheumatoid Arthritis Diagnosis
Michelle J. Ormseth¹, Joseph F. Solus², Quanhu Sheng², Yan Guo², Fei Ye², Ryan Allen², Kasey Vickers² and C Michael Stein², ¹Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Small noncoding RNAs (sRNAs), such as microRNAs (miRNAs), are regulators of biological processes and serve as important biomarkers of disease. Most previous plasma sRNA…
Abstract Number: 1371 • 2017 ACR/ARHP Annual Meeting
Development of an Adjusted Multi-Biomarker Disease Activity (MBDA) Score for Rheumatoid Arthritis (RA) That Accounts for Age, Sex and Adiposity, with Subsequent Evaluation of Ability to Predict Risk for Radiographic Damage
Jeffrey R. Curtis¹, Darl D. Flake II², Michael Weinblatt³, Nancy A. Shadick⁴, Mikkel Østergaard⁵, Merete Lund Hetland⁶, Cecilie Heegaard Brahe⁶, Yong Gil Hwang⁷, Daniel E. Furst⁸, Vibeke Strand⁹, Carol J. Etzel¹⁰, Dimitrios A. Pappas¹¹, Xingbin Wang¹², Ching Chang Hwang¹³, Eric H. Sasso¹², Alexander Gutin², Elena Hitraya¹² and Jerry S. Lanchbury², ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Myriad Genetics Inc., Salt Lake City, UT, ³Brigham and Women’s Hospital, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁷Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Stanford University, Palo Alto, CA, ¹⁰Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ¹¹Columbia University, New York, NY, ¹²Crescendo Bioscience Inc., South San Francisco, CA, ¹³Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The MBDA score, based on 12 serum proteins, is a validated tool for assessing disease activity in RA patients. MBDA biomarkers may be influenced…
Abstract Number: 1865 • 2017 ACR/ARHP Annual Meeting
Novel Approach to Arthritis Surveillance Suggests a Much Higher Prevalence of Arthritis Among US Adults Than Previous Estimate
S. Reza Jafarzadeh and David T. Felson, Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Current national estimates of arthritis prevalence in the United States rely on a single survey question about doctor-diagnosed arthritis from the National Health Interview…
Abstract Number: 1900 • 2017 ACR/ARHP Annual Meeting
Effect of Age and Body Mass Index (BMI) on Multi-Biomarker Disease Activity (MBDA) Score in Patients with Rheumatoid Arthritis
Kerri Ford¹, David Chernoff¹, Xingbin Wang¹, Eric H. Sasso¹, Carol J. Etzel^2,3 and Dimitrios A. Pappas^3,4, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴Columbia University, New York, NY
Background/Purpose: We evaluated the associations between MBDA score and age and between MBDA score and BMI in patients with rheumatoid arthritis (RA). These relationships may…
Abstract Number: 1919 • 2017 ACR/ARHP Annual Meeting
The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity
Chaim Putterman¹, Michelle Petri², Roberto Caricchio³, Jim C. Oates⁴, Pennina Safer⁵, Keren Jakobi-Brook⁵, Rachel Sorek⁵, Ilana Gluzman⁵, Steve Wallace⁶ and Irun R. Cohen^5,7, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Temple Lupus Clinic, Temple University, Philadelphia, PA, USA, Philadelphia, PA, ⁴Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁵ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁶ImmunArray Inc., VA, USA, Richmond, VA, ⁷Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: We have developed the iCHIP1,2 to profile repertoires of serum autoantibodies. The first iCHIP application was the SLE-key RuleOut test3,4 , to rule out…
Abstract Number: 2312 • 2017 ACR/ARHP Annual Meeting
Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Quest Diagnostics Nichols Institute, clemente, CA, ⁵Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁶Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 2871 • 2017 ACR/ARHP Annual Meeting
Anti-RA33 (hnRNP-A2/B1) Autoantibodies Are Associated with the Therapeutic Response to Methotrexate and Anti-TNF Treatment in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Paul Studenic¹, Farideh Alasti², Daniel Aletaha³, Josef S. Smolen¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Besides the determination of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), anti-RA33 antibodies (which are directed to the nuclear antigen hnRNP-A2/B1) could be…
Abstract Number: 2993 • 2017 ACR/ARHP Annual Meeting
Knee Joint Sounds: A Non-Invasive Modality for Classifying Knee Joint Health in Juvenile Idiopathic Arthritis
Daniel Whittingslow¹, Beren Semiz², Lori Ponder³, Patricia Vega-Fernandez⁴, Omer Inan⁵ and Sampath Prahalad⁶, ¹Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ²Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁵Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, ⁶Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common, chronic, childhood rheumatic disease and an important cause of disability. It is characterized by persistent inflammation…
Abstract Number: 172 • 2017 ACR/ARHP Annual Meeting
Optimizing Precision Medicine By Using Genetics to Assign Diagnostic Prior Probabilities to Patients with Synovitis
Rachel Knevel^1,2,3,4, Chikashi Terao^5,6,7, Jing Cui^1,8, Kamil Slowikowski^2,9,10, TWJ Huizinga³, Elizabeth Karlson¹¹ and Soumya Raychaudhuri^1,2,12,13, ¹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Medical and Population Genetics Program, Broad Institute of MIT and Harvard, Cambridge, MA, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Bosten, MA, ⁵Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, ⁶Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, ⁷Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹⁰Division of Genetics, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Department of Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ¹³Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: As the cost of genome-wide genotyping plummets, and biobanking efforts integrating medical records and genetics are rapidly expanding, many patients will have genotyping available…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 581 • 2017 ACR/ARHP Annual Meeting
Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort
Janneke de Winter¹, Marleen van de Sande¹, Niklas Thomas Baerlecken², Inger Berg³, Roberta Ramonda⁴, Désirée van der Heijde⁵, Floris van Gaalen⁶, Torsten Witte⁷ and Dominique Baeten^1,8, ¹Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Rheumatology, Private Practice, Cologne, Germany, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁸UCB Pharma, Slough, United Kingdom
Background/Purpose: Anti-CD74 IgG antibodies are reported to be elevated in serum of patients with axial spondyloarthritis (axSpA). This study aimed to assess the diagnostic value…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].